Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 86

1.

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.

Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, Kayal R, Sanguineti G, Marchetti P, Botticelli A, Marinelli D, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Tonini G, Santini D, Michelotti A, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Cazzaniga M, Moscetti L, Fabbri A, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Garufi C, Di Stefano P, Mirabelli R, Veltri E, Paris I, Giotta F, Lorusso V, Landucci E, Ficorella C, Roselli M, Adamo V, Ricciardi G, Russo A, Valerio MR, Berardi R, Pistelli M, Cannita K, Zamagni C, Garrone O, Baldini E, Livi L, Meattini I, Del Medico P, Generali D, De Maria R, Risi E, Ciliberto G, Villa A, Sperduti I, Mazzotta M, Barba M, Giordano A, Vici P.

J Cell Physiol. 2020 Jan 15. doi: 10.1002/jcp.29445. [Epub ahead of print]

PMID:
31943171
2.

T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.

Conte B, Fabi A, Poggio F, Blondeaux E, Dellepiane C, D'Alonzo A, Buono G, Arpino G, Magri V, Naso G, Presti D, Mura S, Fontana A, Cognetti F, Molinelli C, Pastorino S, Bighin C, Miglietta L, Boccardo F, Lambertini M, Del Mastro L; Gruppo Italiano Mammella (GIM) study group.

Clin Breast Cancer. 2019 Oct 24. pii: S1526-8209(19)30671-8. doi: 10.1016/j.clbc.2019.09.001. [Epub ahead of print]

PMID:
31735691
3.

Chronic prostatic infection: Microbiological findings in two Mediterranean populations.

Stamatiou K, Magri V, Perletti G, Papadouli V, Recleiti N, Mamali V, Zarkotou O.

Arch Ital Urol Androl. 2019 Oct 2;91(3). doi: 10.4081/aiua.2019.3.177.

4.

Green tea catechins for chemoprevention of prostate cancer in patients with histologically-proven HG-PIN or ASAP. Concise review and meta-analysis.

Perletti G, Magri V, Vral A, Stamatiou K, Trinchieri A.

Arch Ital Urol Androl. 2019 Oct 2;91(3). doi: 10.4081/aiua.2019.3.153. Review.

5.

Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.

Cicero AFG, Allkanjari O, Busetto GM, Cai T, Larganà G, Magri V, Perletti G, Robustelli Della Cuna FS, Russo GI, Stamatiou K, Trinchieri A, Vitalone A.

Arch Ital Urol Androl. 2019 Oct 2;91(3). doi: 10.4081/aiua.2019.3.139. Review.

6.

Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients.

Magri V, Gottfried T, Di Segni M, Urban D, Peled M, Daher S, Stoff R, Bar J, Onn A.

Cancer Manag Res. 2019 Sep 5;11:8201-8207. doi: 10.2147/CMAR.S210958. eCollection 2019.

7.

Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer.

Nicolazzo C, Raimondi C, Gradilone A, Emiliani A, Zeuner A, Francescangeli F, Belardinilli F, Seminara P, Loreni F, Magri V, Tomao S, Gazzaniga P.

Cancers (Basel). 2019 Jul 24;11(8). pii: E1042. doi: 10.3390/cancers11081042.

8.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P.

Int J Cancer. 2020 Apr 1;146(7):1917-1929. doi: 10.1002/ijc.32583. Epub 2019 Aug 7.

PMID:
31330065
9.

Prostatic calcifications are associated with a more severe symptom burden in men with type II chronic bacterial prostatitis.

Stamatiou K, Magri V, Perletti G, Trinchieri A, Lacroix R, Rekleiti N, Moschouris H.

Arch Ital Urol Androl. 2019 Jul 2;91(2). doi: 10.4081/aiua.2019.2.79.

10.

Levofloxacin for NIH Category II Chronic Bacterial Prostatitis: A Real-Life Study.

Magri V, Perletti G, Cai T, Stamatiou K, Trinchieri A, Montanari E.

Chemotherapy. 2019;64(1):8-16. doi: 10.1159/000499034. Epub 2019 May 21.

PMID:
31112957
11.

A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer.

Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, Coppa A, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V, Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G.

Cancers (Basel). 2019 Jan 27;11(2). pii: E147. doi: 10.3390/cancers11020147.

12.

Multidisciplinary approach to prostatitis.

Magri V, Boltri M, Cai T, Colombo R, Cuzzocrea S, De Visschere P, Giuberti R, Granatieri CM, Latino MA, Larganà G, Leli C, Maierna G, Marchese V, Massa E, Matteelli A, Montanari E, Morgia G, Naber KG, Papadouli V, Perletti G, Rekleiti N, Russo GI, Sensini A, Stamatiou K, Trinchieri A, Wagenlehner FME.

Arch Ital Urol Androl. 2019 Jan 18;90(4):227-248. doi: 10.4081/aiua.2018.4.227.

13.

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Aroldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P.

J Cell Physiol. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10.

PMID:
30536609
14.

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.

Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P.

Cancer Biol Ther. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7.

15.

Resistance of uropathogens to antibacterial agents: Emerging threats, trends and treatments.

Perletti G, Magri V, Cai T, Stamatiou K, Trinchieri A, Montanari E.

Arch Ital Urol Androl. 2018 Jun 30;90(2):85-96. doi: 10.4081/aiua.2018.2.85. Review.

16.

Computer-Assisted Quantitative Assessment of Prostatic Calcifications in Patients with Chronic Prostatitis.

Boltri M, Magri V, Montanari E, Perletti G, Trinchieri A.

Urol Int. 2018;100(4):450-455. doi: 10.1159/000486346. Epub 2018 Apr 26.

PMID:
29698941
17.

Automated classification of focal breast lesions according to S-detect: validation and role as a clinical and teaching tool.

Di Segni M, de Soccio V, Cantisani V, Bonito G, Rubini A, Di Segni G, Lamorte S, Magri V, De Vito C, Migliara G, Bartolotta TV, Metere A, Giacomelli L, de Felice C, D'Ambrosio F.

J Ultrasound. 2018 Jun;21(2):105-118. doi: 10.1007/s40477-018-0297-2. Epub 2018 Apr 21.

18.

The association between prostatitis and prostate cancer. Systematic review and meta-analysis.

Perletti G, Monti E, Magri V, Cai T, Cleves A, Trinchieri A, Montanari E.

Arch Ital Urol Androl. 2017 Dec 31;89(4):259-265. doi: 10.4081/aiua.2017.4.259.

19.

Chlamydia trachomatis versus common uropathogens as a cause of chronic bacterial prostatitis: Is there any difference? Results of a prospective parallel-cohort study.

Cai T, Pisano F, Nesi G, Magri V, Verze P, Perletti G, Gontero P, Mirone V, Bartoletti R.

Investig Clin Urol. 2017 Nov;58(6):460-467. doi: 10.4111/icu.2017.58.6.460. Epub 2017 Oct 31.

20.

Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence.

Caponnetto S, Gelibter A, Mosillo C, Magri V, Scagnoli S, Pomati G, Piesco G, Verkhovskaya S, Pisegna S, Sirgiovanni G, Napoli V, Buscicchio D, Iannantuono GM, Marinelli D, Mammone G, Pannunzio S, Nicolo' E, Stefani A, Astorino V, Mancini M, Cortesi E.

Ann Oncol. 2017 Oct;28 Suppl 6:vi51. doi: 10.1093/annonc/mdx425.026. No abstract available.

Supplemental Content

Support Center